No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GPCR Structure Therapeutics
- 44.660
- +0.140+0.31%
Close Jul 16 16:00 ET
- 40.370
- -4.290-9.61%
Pre 07:52 ET
2.49BMarket Cap-21317P/E (TTM)
47.480High42.620Low1.45MVolume44.790Open44.520Pre Close64.74MTurnover3.76%Turnover RatioLossP/E (Static)55.69MShares75.01752wk High5.79P/B1.72BFloat Cap25.57052wk Low--Dividend TTM38.40MShs Float75.017Historical High--Div YieldTTM10.92%Amplitude20.800Historical Low44.803Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Peering Into Structure Therapeutics's Recent Short Interest
Structure Therapeutics's (NYSE:GPCR) short percent of float has risen 31.9% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 19.35% of all
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
JMP Securities analyst Jonathan Wolleben maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $91.According to TipRanks data, the analyst has a success
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Pfizer Signals Progress on Obesity Pill, Boosting Stock
By Ciara Linnane and Eleanor Laise Oral versions of popular weight-loss drugs could be cheaper, more accessible, analysts say Pfizer Inc.'s stock (PFE) rose 2.8% early Thursday, after the drug
Comments
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US$
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
